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Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease
of the central nervous system (CNS), characterized by pathogenic, complement-activating
autoantibodies against the main water channel in the CNS, aquaporin 4 (AQP4). NMOSD
is frequently associated with additional autoantibodies and antibody-mediated diseases.
Because the alternative pathway amplifies complement activation, our aim was to evaluate
the presence of autoantibodies against the alternative pathway C3 convertase, its
components C3b and factor B, and the complement regulator factor H (FH) in
NMOSD. Four out of 45 AQP4-seropositive NMOSD patients (~9%) had FH
autoantibodies in serum and none had antibodies to C3b, factor B and C3bBb. The FH
autoantibody titers were low in three and high in one of the patients, and the avidity
indexes were low. FH-IgG complexes were detected in the purified IgG fractions by
Western blot. The autoantibodies bound to FH domains 19-20, and also recognized the
homologous FH-related protein 1 (FHR-1), similar to FH autoantibodies associated with
atypical hemolytic uremic syndrome (aHUS). However, in contrast to the majority of
autoantibody-positive aHUS patients, these four NMOSD patients did not lack FHR-1.
Analysis of autoantibody binding to FH19-20 mutants and linear synthetic peptides of the
C-terminal FH and FHR-1 domains, as well as reduced FH, revealed differences in the
exact binding sites of the autoantibodies. Importantly, all four autoantibodies inhibited C3borg April 2021 | Volume 12 | Article 6603821
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Frontiers in Immunology | www.frontiersin.binding to FH. In conclusion, our results demonstrate that FH autoantibodies are not
uncommon in NMOSD and suggest that generation of antibodies against complement
regulating factors among other autoantibodies may contribute to the complement-
mediated damage in NMOSD.Keywords: aquaporin (AQP) 4, complement, factor H, neuromyelitis optica spectrum disorder, autoantibody,
autoimmunity, inflammation, central nervous systemINTRODUCTION
Neuromyelitis optica spectrum disorder (NMOSD) is a rare
inflammatory disease of the central nervous system (CNS) with
a prevalence of 0.7-10/100,000 worldwide (1) and is
characterized by pathogenic complement-activating
autoantibodies against aquaporin 4 (AQP4), the main water
channel of the CNS (2, 3). Most commonly, relapsing and
often bilateral optic neuritis, longitudinally extensive transverse
myelitis, and brainstem symptoms characterize NMOSD (4–7).
Complement is an essential effector system of the humoral
arm of innate immunity (8). The complement system can be
activated via three main pathways, the classical, the lectin and the
alternative pathways. It provides a first-line defense against
infections, participates in the clearance of immune complexes
and cellular waste, and influences adaptive immune responses (8–
10). Complement gene mutations and polymorphisms that result
in altered protein function and thus excessive activation,
inappropriate regulation or failure in proper targeting of
complement attack may lead to pathogenic complement
activation, which by causing inflammation and tissue damage is
implicated in the pathogenesis of several diseases (11). In addition
to genetic alterations, autoantibodies to complement proteins can
cause or contribute to diseases via binding to their target, which
in turn may impair the function of the respective proteins and
result in pathological complement activation (12–14).
Complement has also been implicated in the pathogenesis
of NMOSD. CNS lesions are characterized by deposition of
complement proteins along with IgG, IgM, and loss of
astrocytic AQP4 (15–17). Patients with NMOSD have higher
levels of complement activation products in the blood, and the
three complement pathways are functionally abnormal even
during the remission period (18–20). Autoantibodies to
complement C1q were described in NMOSD patients (19).
Autoantibodies can activate complement via the classical
pathway when bound to their target proteins, which was
recently described for AQP4-autoantibodies, as well (5, 21).
AQP4 autoantibodies, also known as NMO-IgG, mainly belong
to the IgG1 subclass, and astrocytes transfected by AQP4 are
susceptible to cell death by IgG and IgM AQP4-antibodies in the
presence of complement (22, 23). The pathogenic role of NMO-
IgG in the presence of human complement is also supported byremic syndrome; AQP4, aquaporin 4;
ervous system; FB, factor B; FH, factor
OSD, neuromyelitis optica spectrum
org 2the results of passive transfer experiments (5, 21) and in vivo
disease models, where complement inhibition was proven to be
beneficial (24). Moreover, clinical experience also sustains the
role of complement activation in disease pathogenesis, since
treatment with the monoclonal anti-C5 antibody eculizumab
reduced attack frequency, and stabilized or improved
neurological disability of patients with NMOSD (25, 26). Thus,
therapeutic complement inhibition is a promising strategy in the
treatment of NMOSD (24, 27), and eculizumab has been
approved for treating AQP4-IgG positive NMOSD.
Of the three major pathways of complement, the alternative
pathway is particularly powerful because via the so-called
amplification loop it can enhance complement activation
initiated by any complement pathway (8, 28, 29). This is based
on the generation of C3b and formation of the C3bBb alternative
pathway C3 convertase (30). Therefore, proper regulation of the
alternative pathway is essential in maintaining homeostasis.
Antibodies to components of the alternative pathway may
result in a wide spectrum of diseases. Antibodies to the C3
convertase, i.e. C3 nephritic factors (C3NeFs), may stabilize the
convertase resulting in increased complement activation, which
has been associated with C3 glomerulopathies (13, 14, 31).
Autoantibodies to factor H (FH), the major soluble regulatory
protein of the alternative complement pathway, are described in
kidney diseases such as atypical hemolytic uremic syndrome
(aHUS) and dense deposit disease, and are thought to cause
pathogenic complement activation by blocking functional
domains of this complement inhibitor protein (14, 32–34).
FH is a 155-kDa serum glycoprotein that upon binding to
C3b inhibits the activation of the alternative pathway and the
amplification loop. FH acts as a cofactor for the serum protease
factor I in the enzymatic inactivation of C3b (cofactor activity),
prevents assembly of the C3bBb convertase and accelerates its
disassembly if already formed (decay accelerating activity) (35,
36). FH is composed of 20 homologous domains termed short
consensus repeats (SCRs), of which SCR1-4 mediate the cofactor
and decay accelerating activities of the protein, and SCR19-20
function as recognition domains for deposited C3b/C3d in the
context of host surface glycans (37, 38). The physiological
function of FH is critical for proper complement regulation.
Altered FH activity caused by genetic changes and
autoantibodies are associated with several inflammatory and
autoimmune pathologies, such as age-related macular
degeneration, C3 glomerulopathies and aHUS (36, 39).
Overactivation of the complement system was proven to be
present in NMOSD; however, it is unclear what steps lead to
complement activation in the pathogenesis of this disease. WeApril 2021 | Volume 12 | Article 660382
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may contribute to abnormal complement activation in NMOSD.
Therefore, the aim of this study was to evaluate the presence of
antibodies against the alternative pathway convertase C3bBb, its
components C3b and factor B (FB) as well as the regulator
prote in FH in the serum of pat ients with AQP4-
seropositive NMOSD.MATERIALS AND METHODS
Patients
Serum or EDTA-plasma samples of NMOSD patients were
collected after informed consent in accordance with the
Declaration of Helsinki. The study was approved by the
National Ethical Committee (3893.316-12464/KK4/2010 and
42341-2/2013/EKU). Forty-five patients having NMOSD were
included in this study and they all were seropositive for anti-
AQP4 antibody determined by a commercially available cell-
based assay (Euroimmune, Lübeck, Germany). The patients did
not present other autoimmune diseases, cancer or infections.
They were negative for antinuclear antibodies, except for patient
#113; this was a single abnormality, no specific antigen was
identified, and no other systemic autoantibodies (anti-dsDNA,
anti-SSA, anti-SSB) were detected. Characteristics of the FH
autoantibody-positive patients are summarized in Table 1.
Proteins, Sera and Antibodies
Purified human FH, FB, C3b, factor D, C1q, goat anti-human
C1q antibody (Ab) and goat anti-human FH antibody (Ab) were
purchased from Merck (Budapest, Hungary). Human serum
albumin (HSA), bovine serum albumin (BSA), alpha1-
antitrypsin, HRP-conjugated anti-human IgG, HRP-conjugated
anti-human IgA, HRP-conjugated anti-human IgM, and
monoclonal antibodies (mAbs) specific for IgG1, IgG2, IgG3,
IgG4, Ig kappa and Ig lambda were purchased from Sigma-
Aldrich (Budapest, Hungary). HRP-conjugated goat anti-mouse
Ig and HRP-conjugated rabbit anti-goat Ig were purchased from
DakoCytomation (Hamburg, Germany). HRP-conjugated goat
anti-human C3 was from MP Biomedicals (Solon, OH). The
anti-FH mAb A254 was purchased from Quidel (Biomedica,
Budapest, Hungary), and the mAb C18 (40) was from Alexis
Biochemicals (Lörrach, Germany). The anti-FH mAb IXF9 was
described earlier (41).
Codon-optimized sequences of FHR-1, FHR-4B, FH SCRs 1-
4, FH SCRs 8-14, FH SCRs 15-20 were synthesized (GenScript,Frontiers in Immunology | www.frontiersin.org 3Piscataway, NJ) and cloned into the pBSV-8His baculovirus
expression vector, expressed in Spodoptera frugiperda Sf9 cells
and purified by nickel affinity chromatography as described
previously (42, 43). FH SCRs 19-20 and mutant 19-20
fragments were expressed in E. coli (44).
Microtiter Plate Assays
Microtiter plate wells were coated with 5 µg/ml FH, FB, C3b, or
HSA as negative control antigen, for 1 h at 20°C. To measure
autoantibody binding to solid-phase C3bBb convertase, the
convertase was built up in microtiter plate wells as previously
described (45). After blocking with 5% BSA and 0.1% Tween-20
in phosphate buffered saline (BSA-PBS), patients’ serum samples
diluted 1:50 in Dulbecco’s PBS (DPBS; Lonza, Budapest,
Hungary) were added for 1 h. Bound IgG was detected by
incubating the wells with HRP-conjugated anti-human IgG for
1 h. Color reaction was developed with TMB (Kem-En-Tec
Diagnostics, Taastrup, Denmark) and absorbance was
measured at 450 nm. Antibody positivity was determined
based on the reactivity with the specific antigen and the
negative control protein; those having an OD value ≥ the
double of that of the control protein were considered positive.
The identified samples were analyzed in additional assays (see
below) to confirm autoantibody positivity and characterize
specific binding sites and potential functional effects of
the autoantibodies.
To detect IgM and IgA autoantibodies, samples were
preincubated with Protein G-agarose beads (Sigma-Aldrich) to
deplete IgG, and these IgG-depleted samples were added to wells
coated with 5 µg/ml FH. The presence of IgM and IgA
autoantibodies was detected as described above, except for
using the corresponding HRP-conjugated detection antibodies
instead of anti-human IgG. In some assays, prior to
immobilization FH was treated with 10 mM Tris(2-
carboxyethyl)phosphine (TCEP; Sigma-Aldrich) to generate
reduced FH (46). To this end, 20 mM TCEP dissolved in 0.4 M
Tris pH 7.4 was mixed 1:1 with 1 mg/ml FH and incubated for
30 min at 20°C. FH was then diluted and immobilized on
microplate wells, and used for autoantibody binding assay as
described above. Autoantibodies against C1q were analyzed as
described previously (45). Briefly, microtiter plates were coated
with 2 µg/ml C1q and, as negative control antigens, HSA and a1-
antitrypsin. After blocking and washing, serum samples diluted
1:50 in DPBS containing 1 M NaCl were added. Autoantibody
binding was detected with HRP-conjugated anti-human IgG
diluted in DPBS containing 1 M NaCl.
To map the antibody binding sites within FH, recombinant
FH fragments were immobilized and autoantibody binding was
detected as described above. For the characterization of IgG
isotypes, FH and HSA were immobilized and, after blocking with
BSA-PBS, the plates were incubated with patients’ samples. For
the detection, mAbs specific for IgG1, IgG2, IgG3, IgG4, Ig kappa
and Ig lambda, followed by HRP-conjugated goat anti-mouse Ig,
were used. To analyze the effect of anti-FH mAbs, the wells were
incubated with the anti-FH mAbs prior to the addition of
patients’ sera as described (33). To determine the avidity of the
FH autoantibodies, NaSCN as a chaotropic salt was used asTABLE 1 | Characteristics of NMOSD patients with FH autoantibodies.
Age at onset (y) Diagnosis AQP4-Ab
NMO64 23 relapsing ON and LETM +
NMO84 41 relapsing ON and LETM +
NMO113 54 relapsing ON and LETM +
NMO210 64 LETM +All four patients positive for FH autoantibodies are female and have NMOSD for >5 years.
All patients have anti-AQP4 antibodies (AQP4-Ab) in their serum as determined by a cell-
based assay. ON: optic neuritis, LETM: longitudinally extensive transverse myelitis.April 2021 | Volume 12 | Article 660382
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patients’ sera, 0.5 M NaSCN was added for 15 min at 20°C and,
after washing, the bound IgG was detected with HRP-conjugated
anti-human IgG. Titers of the samples were calculated based on a
standard curve and avidity index was calculated as the ratio of
bound antibodies in the presence and absence of NaSCN. To
calculate the avidity profile, various concentrations of NaSCN
were used. To measure the inhibitory effect of autoantibodies on
C3b binding, wells were coated with FH19-20 at 5 µg/ml. After
blocking with BSA-PBS, the wells were incubated with 500 µg/ml
purified IgG, then 2 µg/ml C3b was added. C3b-binding was
detected by HRP-conjugated anti-human C3.
Western Blot
The presence of native FHR-1 was analyzed by Western blotting.
To this end, 0.4 µl patient serum diluted in non-reducing sample
buffer was run on 10% SDS-PAGE. Proteins were blotted onto a
nitrocellulose membrane, and after blocking, the membrane was
incubated with the anti-FH mAb C18, which recognizes both FH
and FHR-1 (40), followed by HRP-conjugated goat anti-mouse Ig.
The blot was developed using the ECL detection kit (Merck).
IgG Isolation and Analysis
10 µl serum diluted in DPBS was incubated with protein G beads
(Life Technologies, Budapest, Hungary) for 2 h at 20°C. After
washing, the bound IgG fraction was eluted with non-reducing
sample buffer and analyzed for the presence of FH and FHR-1 by
SDS-PAGE and Western blotting using the anti-FH mAb C18
followed by HRP-conjugated goat anti-mouse Ig for detection.
For epitope analysis of FH autoantibodies immobilized
peptides were used. To this end, acetylated linear 15-mer
peptides overlapping in 10 amino acids, and covering the FH
SCRs 19-20 (amino acids 1107-1231) as well as their S1191L and
V1197A modified peptides corresponding to the homologous
FHR-1 sequence were designed. The peptides were prepared in
duplicates on functionalized hydroxypropylmethacrylate non-
cleavable gears of a nominal capacity of 66 nmol (Mimotopes,
Clayton Victoria, Australia) by solid phase Fmoc/tBu peptide
synthesis according to Geysen’smethod (49), as described earlier (50),
with slight modifications. Briefly, the Fmoc protecting groups were
removed by 2 v/v% piperidine/2 v/v% 1,8-diazabicyclo[5.4.0]undec-7-
ene in N,N-dimethylformamide, the Fmoc-protected amino acid
derivatives were coupled by N,N′-diisopropylcarbodiimide/1-
hydroxybenzotriazole in N,N-dimethylformamide using ~200 eq
reagents. After building up the peptide chains, the N-terminal a-
amino groupwas acetylated and the side chain protecting groupswere
cleavedwith TFA/thioanisole/phenol/water/EDT82.5:5:5:5:2.5 (v/v/v/
v/v).) The peptides remained covalently attached to the gears andwere
used in linear epitope mapping of the anti-FH autoantibodies.
Autoantibody binding to the synthetic peptides was detected
using a modified ELISA described earlier (51). After blocking the
non-specific binding sites with 0.5% gelatin in PBS, the gears
were incubated with 150 ml of 1:600 diluted sera in PBS/0.5%
gelatin/0.05% Tween-20 for 1 h at 20°C. Autoantibody binding
was detected using HRP-conjugated rabbit anti-human IgG
(DakoCytomation) and TMB detection system. Gears were
used repeatedly after thorough cleaning by sonication in PBSFrontiers in Immunology | www.frontiersin.org 4containing 1% SDS and 0.1% 2-mercaptoethanol. The ODs were
normalized by the following formula: ODsample/ODmin, where
ODsample is the mean of duplicate OD values of the test samples
and ODmin represents the mean binding to the negative control
HSP 480-489 peptide, chosen based on our previous study (50).
Data were further normalized to OD obtained with sera of
healthy controls.RESULTS
Identification of FH Autoantibodies in
NMOSD Sera
In order to identify autoantibodies to complement proteins in
sera of NMOSD patients, ELISA was performed using
immobilized FH, C3b and FB, as well as solid-phase C3bBb
convertase. Of the 45 samples analyzed, four were positive for FH
autoantibodies (i.e., ~ 9%), and specific autoantibodies to C3b,
FB or C3bBb were not detected in any of the samples (Figure 1
and data not shown). Some samples showed high background
binding; these were considered negative for the autoantibodies if
binding to all antigens, including HSA, was similar. In addition,
we depleted IgGs from these autoantibody positive samples to
facilitate the detection of IgM and IgA isotype FH
autoantibodies, if present. There was no specific signal detected
for these samples, except for the IgG-depleted serum of patient
#210, where slight IgA positivity was observed (Supplementary
Figure 1). We also tested the presence of autoantibodies to C1q;
a few but none of the FH autoantibody positive NMOSD serum
samples were positive for C1q autoantibodies (Supplementary
Figure 2), confirming previous report (19).
Because FH autoantibodies are strongly associated with the
deletion of the CFHR1 gene in aHUS (52, 53), we investigated the
sera of the above four patients for the presence of FHR-1 protein,
since DNA samples were not available. The patients did not
receive plasma treatment, thus exogenous origin of FHR-1 could
be excluded. All four patients had both FHR-1 isoforms in their
serum as detected by Western blot analysis (Figure 2).
We also analyzed the presence of FH-autoantibody immune
complexes in the patients’ sera. To this end, IgG was precipitated
using Protein G beads, and the bound proteins were eluted and
analyzed by Western blot using the anti-FH mAb C18. FH was
detected in the sera of patients #64, #84 and #210, displaying
stronger bands compared with the IgG of a healthy individual,
used as control (Figure 3). In addition, FHR-1 was detected in
the case of patient #210, indicating cross-reactivity of the FH
autoantibody with FHR-1 (Figure 3).
Biological Features (Isotype, Titer, Avidity)
of the FH Autoantibodies
Next, we determined the isotypes of the FH autoantibodies by
ELISA. The FH autoantibodies were of the IgG3 isotype in all
four patients, and had k light chains, except for #210, who had l
light chains. The autoantibody titers were determined by
applying serial serum dilutions on HSA- and FH-coated
microtiter plate wells. The autoantibody titers of three of theApril 2021 | Volume 12 | Article 660382
Uzonyi et al. Factor H-Autoantibodies in Neuromyelitis Opticapatients were low (#64, 1:200; #84, 1:100, and #113, 1:200) and
one (#210, 1:800) was higher, similar to a typical, autoimmune
aHUS-associated high-titer anti-FH antibody, used as
positive control.
The avidity of the autoantibodies was determined using
NaSCN to dissociate the FH-bound autoantibodies. A relativelyFrontiers in Immunology | www.frontiersin.org 5low NaSCN concentration (0.5 M) was sufficient to dissociate the
majority of the autoantibodies (Figure 4A). Autoantibodies of
#210 showed slightly higher avidity, since ~80% of the
autoantibodies were able to bind to FH at 0.25 M NaSCN, in
contrast to the other patients’ autoantibodies. The small values of
avidity indexes calculated at 0.5 M NaSCN (Figure 4B) indicated
relatively low-avidity interaction between the autoantibodies of
these NMOSD patients and FH.
NMOSD-Associated FH Autoantibodies
Bind to the FH C Terminus
Recombinant deletion mutants of FH, recombinant FHR-1 and, as
a control, FHR-4B protein were used to determine the binding
domains within FH. All four autoantibodies bound to the C-
terminal domains of FH and cross-reacted with FHR-1 (Table 2).
However, the binding profiles were slightly different: the three
samples with low autoantibody titers bound strongly to FH15-20,
FH19-20 and FHR-1, and comparatively weaker to purified, full-
length FH, whereas the sample of patient #210, which showed a
high background in ELISA and had relatively higher autoantibody
titer, showed very weak binding to FH15-20, but bound equally
well to FH19-20, FH and FHR-1 (Table 2).
To confirm and further characterize the binding site of these
FH autoantibodies, two C-terminally binding mAbs against FH
were used in competition assays. The inhibition profiles were
heterogeneous. The mAb C18 recognizing an epitope in SCR20
(44) caused ~30% and ~50% inhibition of autoantibody bindingFIGURE 1 | Screening of NMOSD sera for autoantibodies by ELISA. Microplate wells were coated with human serum albumin (HSA), FH, FB and C3b, and after
blocking, incubated with sera of 45 NMOSD patients and controls (all serum samples diluted 1:50 in PBS). Binding of autoantibodies to these antigens was detected
using HRP-conjugated anti-human IgG. Serum sample of a patient with atypical hemolytic uremic syndrome (aHUS) and of a patient with dense deposit disease
(DDD), positive for FH and FB autoantibodies, respectively, were used as positive controls. NHS: normal human serum. Data are means of two measurements.
Some samples showed reactivity or high background with all four antigens, and these were considered autoantibody negative. The four samples #64, #84, #113 and
#210 showing clearly stronger reactivity with FH compared to reactivity with HSA, FB and C3b, were considered autoantibody positive.FIGURE 2 | Western blot analysis of NMOSD sera for FHR-1 protein. 0.4 µl
of serum samples were run on 10% SDS-PAGE and the blot was developed
using the anti-FH mAb C18. The two isoforms of factor H-related protein 1
(FHR-1) are seen in the 4 FH autoantibody positive NMOSD patients (64, 84,
113, 210), in an NMOSD patient (301) negative for FH autoantibody, and in a
healthy control sample (NHS). FHR-1 is missing in a FH autoantibody positive
aHUS patient, used as a control sample, as typical for ~90% of aHUS patients
with FH autoantibodies. The blot is representative of two experiments.April 2021 | Volume 12 | Article 660382
Uzonyi et al. Factor H-Autoantibodies in Neuromyelitis Opticato FH in the case of patients #113 and #210, respectively, whereas
it had no significant inhibitory effect in the case of patients #64
and #84. The mAb IXF9 recognizing an epitope within FHFrontiers in Immunology | www.frontiersin.org 6SCR18-19 (41) inhibited autoantibody binding to FH by ~30%
in the case of patients #64, #84 and #113, whereas its slight
inhibitory effect did not reach statistical significance in the case
of patient #210 (Figure 5). In the case of a control sample from
an FH autoantibody positive aHUS patient, mAb IXF9 did not
inhibit autoantibody binding to FH, but mAb C18 almost
completely blocked autoantibody binding (Figure 5).
To further analyze the autoantibody binding sites, 14
recombinant FH19-20 fragments with different single amino
acid exchanges were used. With this approach, in the case of
patient #210 strongly reduced autoantibody binding (50% or less
binding) to the R1182A, W1183L, K1186A, K1188A and E1198A
mutants was found, indicating that these residues are included in
the binding site of the autoantibody (Figure 6). This site is within
the hypervariable loop of FH SCR20 and coincides with the
autoantibody epitope identified for most aHUS patients, as well
as with the binding epitope of mAb C18 (44, 47, 54). Using the
three other patients’ sera, no significant reduction in
autoantibody binding to any of the tested mutants was found,
except for ~25% or less inhibition of binding to the D1119G,
K1186A and E1198A mutants in the case of #64, suggesting that
their binding epitope lies elsewhere in SCR19 or SCR20.A B
FIGURE 4 | Avidity of FH autoantibodies. Avidity of the FH autoantibodies was determined by ELISA using NaSCN as a chaotropic agent. (A) Avidity profile of the
autoantibodies. Residual binding of the FH autoantibodies from serum was measured after applying various NaSCN concentrations. Data are normalized to binding
in the absence of NaSCN (=100% binding). A representative experiment out of two is shown. (B) Avidity indexes calculated at 0.5 M NaSCN. Avidity index is
calculated as the ratio of remaining bound autoantibody after NaSCN elution (AU/ml)/autoantibody bound without NaSCN elution (AU/ml). Data are means ± SD of
three measurements.TABLE 2 | Summary of autoantibody binding sites on FH.
NMO64 NMO84 NMO113 NMO210
FH (+) (+) (+) +
FH1-4 - - - -
FH8-14 – – – –
FH15-20 + + + (+)
FH19-20 + + + +
FHR-1 + + + +
FHR-4B – – – –April 2021 | Volume 12 | ArticThe binding sites of the autoantibodies were determined using recombinant FH fragments
containing domains 1-4 (FH1-4), 8-14 (FH8-14), 15-20 (FH15-20) and 19-20 (FH19-20),
purified FH, the recombinant FH-related FHR-1 and FHR-4B proteins, the latter used as a
negative control.
“(+)” indicates weak binding, “+” indicates prominent binding, “-” indicates no binding.FIGURE 3 | Detection of FH–autoantibody complexes. Western blot analysis
of the IgG fractions for FH/FHR-1 – IgG complexes. 10 µl of serum samples
were incubated with Protein G beads. The bound proteins, eluted with SDS-
sample buffer, were run on 10% SDS-PAGE, transferred to nitrocellulose
membrane, and the blot was developed with monoclonal anti-FH recognizing
also FHR-1 (mAb C18). FH is detected in the FH-autoantibody positive
NMOSD patients (NMO64, NMO84, NMO210), but not in the FH-
autoantibody negative (NMO176) or healthy control sample. In addition, FHR-
1 is also seen in the NMOSD sample with the highest autoantibody titer
(NMO210). Normal human serum (NHS) was run as a control. The blot is
representative of three experiments.le 660382
Uzonyi et al. Factor H-Autoantibodies in Neuromyelitis OpticaLinear epitope mapping of the autoantibodies was performed
by peptide analysis using overlapping 15-mer peptides covering
FH19-20. A heterogeneity of the binding sites of the
autoantibodies was clearly detectable. Samples of #64 and #113
were positive for peptides derived from SCR19, the sample #210Frontiers in Immunology | www.frontiersin.org 7reacted with peptides in SCR20, whereas autoantibodies of #84
bound to peptides of both SCRs (Figure 7A). Peptides
corresponding to the differences in the FH SCR20-homolog
domain of FHR-1, i.e. including the FH S1191L and V1197A
amino acid exchanges, were also synthesized and analyzed. TheFIGURE 5 | Inhibition of autoantibody binding to FH by mAbs. Immobilized FH was preincubated with the anti-FH mAbs A254 (binding in SCR1), C18 (binding in
SCR20) and IXF9 (binding in SCR18-19), then serum samples of the FH autoantibody positive four NMOSD patients and of an aHUS patient, used as control, were
added to the wells. Autoantibody binding was detected by HRP-conjugated anti-human IgG. Data are normalized to autoantibody binding in the absence of mAb.
Data are mean ± SD of three measurements. *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA.April 2021 | Volume 12 | Article 660382
Uzonyi et al. Factor H-Autoantibodies in Neuromyelitis Opticapeptide reactivity by the autoantibodies confirmed the cross-
reactivity of the NMOSD-associated FH autoantibodies with
FHR-1; interestingly, the sample of patient #210 showed
strongly increased binding to the FHR-1 peptide 286-300 in
comparison with the corresponding FH peptide 1187-1201
(Figure 7B). The identified peptides are shown on the FH19-
20 structure in Figure 7C.
The SCR19 peptide 1114-PIDNGDIT-1121 was previously
identified as a binding site for FH-autoantibodies detected in
patients with non-small cell lung cancer, and the autoantibodies
recognized FH particularly when FH was reduced. To further
characterize the NMOSD-associated FH autoantibodies in this
regard, the binding of autoantibodies to FH and TCEP-treated,Frontiers in Immunology | www.frontiersin.org 8reduced FH was compared. In this assay, the three samples that
showed SCR19 reactivity in the epitope mapping assays, #64, #84
and #113 showed markedly increased binding to reduced FH,
whereas in the case of #210 and an aHUS patient sample with
known SCR20-binding autoantibodies, reduction of FH did not
result in enhancement of reactivity (Figure 8).
FH Autoantibodies of NMOSD Patients
Inhibit the Interaction of FH With C3b
To assess whether FH autoantibodies of the NMOSD patients
interfere with FH function, we analyzed the interaction of C3b
with the FH19-20 fragment in the presence of the autoantibodies.
IgG of patients #64 and #84 inhibited C3b binding to FH19-20 byFIGURE 6 | Epitope mapping using mutant FH19-20 fragments. The wild type FH19-20 fragment and 14 mutants containing single amino acid exchanges were
immobilized in microtiter plate wells and incubated with patient serum. Autoantibody binding was detected using HRP-conjugated anti-human IgG. Data are mean ±
SD of three experiments. *p < 0.05 and ***p < 0.001, one-way ANOVA.April 2021 | Volume 12 | Article 660382
Uzonyi et al. Factor H-Autoantibodies in Neuromyelitis Optica~40%, IgG of patient #113 by ~30%, and that of patient #210 by
~70%. By contrast, IgG derived from healthy individuals or
NMOSD patients without autoantibodies to FH did not affect
C3b binding (Figure 9).DISCUSSION
Anti-complement autoantibodies are involved in several different
diseases (12–14). Formost autoantibodies a directly pathogenic role
is not proven and therefore amatter of debate, such as in the case of
C3NeF. FH autoantibodies appear pathogenic in aHUS and dense
deposit disease, as functional consequence of the presence of the
autoantibodies was described in terms of interfering with the
interaction of FH with C3b and host cells and with the cofactor
activity of FH, respectively (33, 34). FH autoantibodies are reported
in 8-25% of aHUS patients in different cohorts and are stronglyFrontiers in Immunology | www.frontiersin.org 9associated with homozygous deletion of the CFHR1 gene, but are
more rarely reported in patients with C3 glomerulopathies
including dense deposit disease (32, 53, 55). On the other hand,
FH autoantibodiesmight have a protective role such as described in
patientswithnon-small cell lung cancer (46, 56). FHautoantibodies
were also reported in inflammatory, autoimmune diseases where
their role is less clear (57, 58). Inaddition, autoantibodies against the
C3bBb convertase and its components C3b and FB are described in
diseases associated with alternative complement pathway
dysregulation (14, 45, 59–61). Therefore, we studied whether
autoantibodies against C3bBb, C3b, FB and FH occur in
NMOSD, a spectrum disease characterized by pathological
complement activation.
FH autoantibodies were detected in four out of 45 NMOSD
serum samples (~9%), while no antibodies against C3b, FB and
C3bBb were found in these samples (Figure 1). The relevance of
C1q autoantibodies that were detected in some samplesA B
C
FIGURE 7 | Linear epitope mapping of the FH autoantibodies. Overlapping 15-mer solid phase peptides (A) covering the 19-20 domains of FH and (B) containing
the FH S1191L and V1197A FHR-1 specific amino acid exchanges (indicated by yellow highlighting) were incubated with patients’ sera. Autoantibody binding was
detected using HRP-conjugated anti-human IgG, and is expressed as ratio of ODsample/ODmin, where ODsample is the mean of duplicate OD values of the
patients’ samples, while ODmin represents the mean antibody binding to the negative control HSP480-489 peptide. On the y axis the initial and final amino acid of
each tested peptide is displayed with the single-letter amino acid sequence indicated in between. (C) The schematic picture of the FH C-terminal domains shows the
identified epitopes highlighted in red (1112-1121), green (1132-1146) and blue (1212-1221), corresponding to the color codes of the one-letter amino codes in A.April 2021 | Volume 12 | Article 660382
Uzonyi et al. Factor H-Autoantibodies in Neuromyelitis Optica(Supplementary Figure 2) should be investigated in the future.
Three of the four identified FH autoantibodies were similar to
each other by having low-titer, low-avidity autoantibodies and
displaying identical binding profile to FH domains. The fourth
autoantibody, that of patient #210, was clearly different and
resembled more the aHUS-associated antibodies than the other
three, by having high-titer FH autoantibodies and binding to the
same hypervariable loop on SCR20 of FH (Figures 5–9) as the
aHUS-associated autoantibodies (44). The autoantibodies bound
to FH domains 19-20, and also recognized the homologous
protein FHR-1, similar to FH autoantibodies associated with
aHUS (44, 62, 63). However, in contrast to most autoantibody-
positive aHUS patients, these four NMOSD patients did not lackFrontiers in Immunology | www.frontiersin.org 10the FHR-1 protein. The clear detectability of native FHR-1 in
immune complexes of patient #210 could have been because of the
higher autoantibody titer and avidity, as well as stronger reactivity
with FHR-1 peptides in the case of this patient compared with the
three other NMOSD patients (Figures 3, 4, 7). In both NMOSD
and aHUS, the IgG3 isotype dominated among the FH
autoantibodies, indicating infection- or inflammation-related
generation of the autoreactive antibodies. Recently, based on the
slight structural differences between the C termini of FH and FHR-
1, and the lack of FHR-1 in most aHUS patients, we proposed a
model for the generation of the aHUS-associated autoantibodies in
the context of infection and induced neo-epitope due to slight
structural change in the FH C terminus upon binding to microbial
proteins (44). Collectively, the results of our experiments suggest a
mechanism of autoantibody generation in the NMOSD patients
different from that in the aHUS patients.
The FH19-20 and FHR-1 peptides recognized by the four
NMOSD autoantibodies are in part similar to those described in
aHUS patients (Figure 7) (54). These include the linear epitopes
1152-1171 inFHSCR19,which showedweak reactivitywith the FH
autoantibody positive NMOSD sera and strong reactivity with
aHUS sera, and the peptides 1207-1226 in FH SCR20. The FH
SCR19 peptides 1107-1131 and 1132-1146 showed reactivity only
with the FH autoantibody positive NMOSD sera, but not with
aHUS sera. The peptides FH SCR20 1177-1191 and the homologue
FHR-1 276-290 showed onlyweak reactivity with theNMOSD sera
compared with the strong reactivity of the autoantibody positive
aHUS sera (Figure 7) (54). The FHR-1 peptide 286-300 showed
strong reactivity with the serum of patient #210, and this peptide
was non-reactive with aHUS sera. Interestingly, FH autoantibodies
found in patients with non-small cell lung cancer recognize the
peptide PIDNGDIT in FH SCR19, inhibit FH binding to lung
carcinoma cells and cause increasedC3-depositionwhenbinding to
FH that is already bound to the cancer cell surface (46). In our
experiments, the linear epitope analysis showed the common
recognition of epitope PPPIDNGDIT (SCR19 1107-1131) by FH
autoantibodies ofpatients #64, #84and#113, and these samples also
showed enhanced reactivity with reduced FH (Figures 7-8). In the
lung cancer study, the patients’ sera reacted strongly with reduced
FH compared with the non-reduced protein, suggesting a cryptic
epitope and/or a cancer-specific, posttranslational modification of
the protein that is recognized by the autoantibodies. Similarly, it is
possible that in NMOSD lesions the ongoing inflammation and
damage of glial cells cause a slightly reducing microenvironment
that may influence the conformation of FH, and allow for
inflammation-driven induction of autoreactivity against this
complement regulator.
Although recognizing different epitopes, autoantibodies of all
patients affected binding of FH to C3b, with that of patient #210
strongly inhibiting the FH-C3b interaction (Figure 9). Since the
interaction of the FHC terminuswithC3b is critical for dockingFH
toC3b-covered surfaces and allowing FH to act as a regulator at the
surface (37, 38, 64), the presence of these interfering autoantibodies
may contribute to ongoing complement activation and damage of
host cell surfaces, e.g. on astrocytes, where complement activation
was initially triggered by NMO-IgG.FIGURE 9 | Inhibition of C3b binding to FH19-20 by FH autoantibodies. The
immobilized FH19-20 fragment was incubated with IgG purified from the sera
of NMOSD patients, healthy human sera (C) or serum of an aHUS patient
with FH autoantibodies, then C3b was added. C3b binding was detected
using HRP-conjugated anti-human C3 antibodies. Data are normalized to
binding in the absence of IgG (=100%) and are means + SD of three
measurements.FIGURE 8 | Autoantibody binding to reduced FH. Microplate wells were
coated with equimolar amounts of HSA, FH and TCEP-treated, reduced FH,
and after blocking, incubated with patients’ sera diluted 1:50 in PBS.
Autoantibody binding was detected by HRP-conjugated anti-human IgG. As
controls, sera of two FH autoantibody-negative NMO patients (#176 and
#193), an aHUS patient and a healthy control (normal human serum, NHS)
were used. Goat antiserum was used to prove that FH and reduced FH were
immobilized on the plate. Data are mean ± SD of two experiments.April 2021 | Volume 12 | Article 660382
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#210, despite having FH autoantibodies with overlapping
characteristics and similar, C-terminal binding sites as the aHUS-
associated FHautoantibodies, didnot havemanifest kidney disease.
This might also be related to the relatively low avidity of the
NMOSD-associated FH autoantibodies or difference in the exact
binding site, compared to FH autoantibodies from aHUS patients’
sera. In addition, a fraction of the autoantibodies could bind FHR-1
instead of FH.However, it is theoretically possible that co-existence
of AQP4-antibodies and FH-antibodies may contribute to
subclinical impairment of kidney functions. Complement
regulators are important in preventing peripheral organ injury in
NMOSD patients and in the animal model of NMOSD (65, 66).
However, the urine proteome and metabolome of NMOSD is
different from multiple sclerosis (67, 68). Whether this reflects
kidney alterations in a subgroup of patients with FHautoantibodies
maybe worth investigating.
A characteristic feature of NMOSD is the increased frequency
of associated autoantibodies and autoimmune diseases.
Antibodies against gastrointestinal antigens may be present
(69), and antinuclear antibodies were detected in 44% of
patients with NMOSD (70). AQP4-antibodies were detected in
patients with rheumatologic diseases in the presence of NMOSD-
associated syndromes (71, 72), and temporal changes in SLE-
associated antibody levels overlap with dynamics of AQP4-
antibodies (73). Generation of autoantibodies against
complement regulators, such as FH may be part of a co-
existing condition in patients with susceptibility to multiple
autoimmunity (72). We also describe that autoantibodies
against the natural complement inhibitor FH in NMOSD
patients impair the interaction of FH with C3b, which is the
basis of its complement regulatory activity. This in turn may
contribute to disease activity.
Limitations of our study include the low patient and sample
number due to the rarity of the disease, and the lackof complement-
active serial serum samples that restricted the breadth and the
power of the analyses. At present, no clear conclusion on the
correlation of the presence of FH autoantibodies with the clinical
manifestation can be drawn. Analysis of additional patient cohorts
and samples is expected to establish the frequency and the biological
characteristics of the FH autoantibodies in NMOSD, and also
whether and how these autoantibodies may contribute to the
pathology of the disease and influence the clinical phenotype.
In conclusion, our results demonstrate that systemic FH
autoantibodies are not uncommon in NMOSD, and they
influence binding of FH to its main ligand, complement C3b.
Our data also suggest that generation of autoantibodies against
complement regulating factors among other autoantibodies may
contribute to the complement-mediated damage in NMOSD.
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